Nicolas Schmitz

🔬 Latest pharma industry updates 👇

🏗️ Eli Lilly and Company invests $4.5B in new Medicine Foundry in Indiana and set to open in 2027.

💔 CVS Health to lay off 2,900 employees amid strategic review, part of a $2 billion cost-cutting plan.

🌍 AzurBio Pharma launches to expedite European market entry for biopharma companies.

🤝 Roche acquires breast cancer drug prospects from Regor Therapeutics Group for $850M.

💰 Aktis Oncology raises $175M for radiopharmaceutical drug development.

🟢 Johnson & Johnson's Yuvanci® approved in the EU for pulmonary hypertension.

🏗️ Grifols plans €360M investment in new engineering headquarters in Barcelona.

💰 Kailera Therapeutics emerges with $400M to develop obesity drugs acquiring assets from Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

⚖️ Georgia judge overturns 6-week abortion ban restoring legal abortion access up to 20-22 weeks of pregnancy.

💰 Pfizer sells $3.26B stake in Haleon, reducing ownership from 22.6% to 15%.

🏭 Johnson & Johnson to invest $2B in new biologics facility in North Carolina.

💰 Merck acquires rights to experimental leukemia drug CN201 for $750M from Curon Biopharmaceutical.

🏢 Chiesi Group inaugurates €380M biotechnology center in Parma, Italy.

📉 Eagle Pharmaceuticals, Inc. to be delisted from Nasdaq due to compliance issues.

✅ FDA declares end to shortages of Eli Lilly and Company's Zepbound and Mounjaro.

🦠 Novavax shares rise 19% amid bird flu outbreaks in Europe.

🤝 Gilead Sciences licenses HIV drug lenacapavir to generic manufacturers royalty-free.

💰 Triveni Bio raises $115M to develop antibody drugs for inflammatory diseases.

📈 Septerna files for IPO to advance hypoparathyroidism treatment.

💰 Sanofi sells Enjaymo® rights to Recordati for $825M upfront.

💰 Editas Medicine sells future license fees to DRI Healthcare for $57M upfront.

📉 Trevena, Inc. to be delisted from Nasdaq after failing equity requirements.

🔬 Latest pharma industry updates 👇

🤝 Johnson & Johnson is set to acquire V-Wave, a heart failure device maker, for up to $1.7 billion.

💉 Bavarian Nordic commits to supplying 2 million doses of its mpox vaccine to Africa this year, with plans to expand production on the continent.

⚠️ A WHO analysis links semaglutide from Novo Nordisk to increased suicide risk, particularly in patients also on antidepressants.

🌱 BridgeBio has spun off several rare disease drug programs into a new company, GondolaBio, backed by $300 million in investment.

👁️ U.S. biotech companies Zenas BioPharma and Bicara Therapeutics file for IPOs, testing a challenging market for drug startups.

💰 Illumina Ventures raises 300 million USD for its 3rd fund.

🟢 Moderna’s RSV vaccine receives EU approval, marking another advance in mRNA technology.

📊 Lundbeck raised its sales and profit forecasts for 2024, driven by higher-than-expected performance from key medications.

🤔 Regeneron confirmed that the FDA won’t approve its multiple myeloma drug due to 3rd party manufacturing issues.

💉 World Health Organization and UNICEF are launching vaccination campaigns in Gaza after a polio case was detected in a 10-month-old baby, the 1st in 25 years.

💼 Bayer's shares rebounded after a Pennsylvania court ruled in favor of its subsidiary Monsanto in a case involving the herbicide Roundup.

🏭 Novo Nordisk is investing $220 million in a new facility in Køge, Denmark, marking the largest investment in its 75-year history.

📈 Alzamend Neuro shares surged 187% after announcing a partnership with Massachusetts General Hospital for a Phase 2 PTSD study.

📊 Cancers linked to lifestyle factors like smoking are decreasing in younger Americans, while other cancers, such as breast and pancreatic, are becoming more prevalent, according to a new study.

🙏 Despite higher cancer rates, mortality is declining due to better detection and treatment.

🔬 Eli Lilly and Company's tirzepatide shows a 94% reduction in Type 2 diabetes progression risk.

🟢 FDA approved Johnson & Johnson’s lung cancer drug combo, Rybrevant and Lazcluze.

📈 InMed Pharmaceuticals reported that its Alzheimer’s candidate, INM-901, shows promising preclinical results, boosting its stock by 191%.

💔 Bayer plans to cut 150 jobs at its Basel site as part of a broader cost-saving initiative, aiming to save €2 billion by 2026.

👁️ Kamala Harris pledges to expand drug price controls if elected, continuing Biden's efforts to lower prescription costs.

🟢 The UK has approved Eisai Co., Ltd.'s Leqembi® for Alzheimer’s, despite its rejection by the EU, citing its efficacy in slowing cognitive decline.

🌍 In Iraq, pollution from war debris and oil extraction has led to a surge in cancer cases, overwhelming healthcare systems and leading to costly treatments.

🧠 Neuralink’s second human surgery enables a spinal injury patient to engage in 3D design and gaming.